This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palmieri, C. Articles by Coombes, R. C. Search for Related Content PubMed PubMed Citation Articles by Palmieri, C. Articles by Coombes, R. C.

The Expression of ERßcx in Human Breast Cancer and the Relationship to Endocrine Therapy and Survival

¹ Department of Cancer Medicine, Cancer Cell Biology Group, Cancer Research UK Laboratories, Imperial College-London, Hammersmith Hospital, London, United Kingdom; ² Department of Medical Oncology, St. George’s Hospital, London, United Kingdom; ³ Department of Histopathology, Imperial College Faculty of Medicine and Charing Cross Hospital, London, United Kingdom; ⁴ Department of Social Science and Medicine, Faculty of Medicine, Imperial College School of Science, Technology and Medicine, London, United Kingdom; and ⁵ Department of Medical Nutrition and Biosciences, Karolinska Institute, Huddinge, Sweden

Purpose: Estrogen receptor (ER) -positive breast cancer is often treated with endocrine therapy using either antiestrogens or aromatase inhibitors. However, 30% of patients who receive endocrine therapy will derive no benefit from such treatments and may indeed suffer adverse effects. Currently, there are no ways to predict response to such treatments. ERßcx, a variant of ERß, has a dominant-negative effect over ER, and its expression thought to modulate response to endocrine treatment may represent a predictor of response to endocrine therapy.

Experimental Design: We investigated the expression of the ERßcx in 82 frozen breast samples (8 benign, 1 ductal carcinoma in situ, and 73 malignant) by Western blot analysis. The relationship between the expression of ERßcx variants with prognosis and outcome of endocrine therapy was examined.

Results: There was a statistically significant association between the presence of ERßcx and the response to endocrine therapy (Fisher’s exact test, P = 0.04). We also examined the influence of the ERßcx status of a tumor on time to progression and death. There was a relationship between the presence of ERßcx and survival, with patients whose tumors express ERßcx having a longer survival rate (P = 0.05). Cell-type specificity of expression was assessed by immunohistochemistry on a selection of histological samples.

Conclusions: On the basis of this small group of patients, we conclude that the expression of ERßcx correlated with favorable response to endocrine therapy. A larger study involving the staining of archival material is currently underway to confirm these preliminary results.

This article has been cited by other articles:

				C. Palmieri, O. Gojis, B. Rudraraju, and S. Cleator Does ER-{beta}cx Really Have No Clinical Importance in Tamoxifen-Treated Breast Cancer Patients? J. Clin. Oncol., December 10, 2008; 26(35): 5824 - 5824. [Full Text] [PDF]

				A. M. Shaaban, A. R. Green, S. Karthik, Y. Alizadeh, T. A. Hughes, L. Harkins, I. O. Ellis, J. F. Robertson, E. C. Paish, P. T.K. Saunders, et al. Nuclear and Cytoplasmic Expression of ER{beta}1, ER{beta}2, and ER{beta}5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients Clin. Cancer Res., August 15, 2008; 14(16): 5228 - 5235. [Abstract] [Full Text] [PDF]

				S Borgquist, C Holm, M Stendahl, L Anagnostaki, G Landberg, and K Jirstrom Oestrogen receptors {alpha} and show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer J. Clin. Pathol., February 1, 2008; 61(2): 197 - 203. [Abstract] [Full Text] [PDF]

				H. Sugiura, T. Toyama, Y. Hara, Z. Zhang, S. Kobayashi, Y. Fujii, H. Iwase, and H. Yamashita Expression of Estrogen Receptor Wild-type and its Variant ER cx/ 2 is Correlated with Better Prognosis in Breast Cancer Jpn. J. Clin. Oncol., November 1, 2007; 37(11): 820 - 828. [Abstract] [Full Text] [PDF]

				W. L Hall, K. Vafeiadou, J. Hallund, S. Bugel, M. Reimann, C. Koebnick, H-J F. Zunft, M. Ferrari, F. Branca, T. Dadd, et al. Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production Am. J. Clinical Nutrition, March 1, 2006; 83(3): 592 - 600. [Abstract] [Full Text] [PDF]

				A Rody, U Holtrich, C Solbach, K Kourtis, G von Minckwitz, K Engels, S Kissler, R Gatje, T Karn, and M Kaufmann Methylation of estrogen receptor {beta} promoter correlates with loss of ER-{beta} expression in mammary carcinoma and is an early indication marker in premalignant lesions Endocr. Relat. Cancer, December 1, 2005; 12(4): 903 - 916. [Abstract] [Full Text] [PDF]

				A. G. Schwartz, G. M. Prysak, V. Murphy, F. Lonardo, H. Pass, J. Schwartz, and S. Brooks Nuclear Estrogen Receptor {beta} in Lung Cancer: Expression and Survival Differences by Sex Clin. Cancer Res., October 15, 2005; 11(20): 7280 - 7287. [Abstract] [Full Text] [PDF]

				K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532. [Abstract] [Full Text] [PDF]

				M. Esslimani-Sahla, A. Kramar, J. Simony-Lafontaine, M. Warner, J.-A. Gustafsson, and H. Rochefort Increased Estrogen Receptor {beta}cx Expression during Mammary Carcinogenesis Clin. Cancer Res., May 1, 2005; 11(9): 3170 - 3174. [Abstract] [Full Text] [PDF]

				M P A Davies, P A O'Neill, H Innes, D R Sibson, W Prime, C Holcombe, and C S Foster Correlation of mRNA for oestrogen receptor beta splice variants ER{beta}1, ER{beta}2/ER{beta}cx and ER{beta}5 with outcome in endocrine-treated breast cancer J. Mol. Endocrinol., December 1, 2004; 33(3): 773 - 782. [Abstract] [Full Text] [PDF]